Chen Jinyan, Li Huigang, Zhuo Jianyong, Lin Zuyuan, Hu Zhihang, He Chiyu, Wu Xiang, Jin Yiru, Lin Zhanyi, Su Renyi, Sun Yiyang, Wang Rongsen, Sun Jiancai, Wei Xuyong, Zheng Shusen, Lu Di, Xu Xiao
Zhejiang University School of Medicine, Hangzhou 310058, China.
Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Hangzhou 310006, China.
Cancer Biol Med. 2024 Dec 24;21(11):1033-49. doi: 10.20892/j.issn.2095-3941.2024.0267.
Pulmonary metastasis is a life-threatening complication for patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). In addition to the common mechanisms underlying tumor metastasis, another inevitable factor is that the application of immunosuppressive agents, including calcineurin inhibitors (CNIs) and rapamycin inhibitors (mTORis), after transplantation could influence tumor recurrence and metastasis. In recent years, several studies have reported that mTORis, unlike CNIs, have the capacity to modulate the tumorigenic landscape post-liver transplantation by targeting metastasis-initiating cells and reshaping the pulmonary microenvironment. Therefore, we focused on the effects of immunosuppressive agents on the lung metastatic microenvironment and how mTORis impact tumor growth in distant organs. This revelation has provided profound insights into transplant oncology, leading to a renewed understanding of the use of immunosuppressants after LT for HCC.
肺转移是接受肝移植（LT）的肝细胞癌（HCC）患者面临的危及生命的并发症。除了肿瘤转移的常见机制外，另一个不可避免的因素是移植后应用免疫抑制剂，包括钙调神经磷酸酶抑制剂（CNIs）和雷帕霉素抑制剂（mTORis），可能会影响肿瘤复发和转移。近年来，多项研究报告称，与CNIs不同，mTORis能够通过靶向转移起始细胞和重塑肺微环境来调节肝移植后的致瘤格局。因此，我们重点研究了免疫抑制剂对肺转移微环境的影响以及mTORis如何影响远处器官的肿瘤生长。这一发现为移植肿瘤学提供了深刻的见解，使人们对LT后HCC患者免疫抑制剂的使用有了新的认识。
